Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 6,936 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control, small Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: BT-001, Control App; Behavioral · Other
Lead sponsor: Better Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • New Orleans, Louisiana • Durham, North Carolina

Conditions: Spinal Fusion
Interventions: Pregabalin, placebo; Drug · Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Infant,Premature
Interventions: Assessment of oxygenation instability, Determination of mechanisms of hypoxemia episodes, Assessment of respiratory instability, apneic threshold of CO2, Assessment of peripheral chemoreceptor function, Assessment of central chemo-receptor function; Other
Lead sponsor: University of Miami; Other
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Anxiety Disorders, Mood Disorders, Insomnia, Nightmares
Interventions: Behavioral Sleep Intervention, Prazosin, Placebo; Behavioral · Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: Nonexercise control group, Aerobic Exercise Group 1, Aerobic Exercise Group 2, Aerobic Exercise Group 3; Behavioral
Lead sponsor: Jeff Burns, MD; Other
Eligibility: 65 Years and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Mild Alzheimer's Disease
Interventions: Non-invasive brainstem stimulation; Device
Lead sponsor: Scion NeuroStim; Industry
Eligibility: 65 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Boca Raton, Florida • Tampa, Florida • Chapel Hill, North Carolina + 2 more

Conditions: Actinic Keratosis
Interventions: ALA, Vehicle, IBL 20 mW, IBL 10 mW; Drug · Device
Lead sponsor: DUSA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more

Conditions: Advanced Malignant Neoplasm, Locally Advanced Malignant Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions: Questionnaire Administration, Video; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cognitive Coping, Cancer
Interventions: Cancer Pain 101, Pharmacotherapy Informational Packet; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: High Intensity Interval Training, Overweight and Obesity, Metabolic Disease, Cognition
Interventions: HIIT Exercise Intervention, Stretching Intervention; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 12 Years to 16 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain Management
Interventions: BreEStim 120, BreEStim 240; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Family-Based Risk Reduction Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 19 Years · Female only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Breast Cancer
Interventions: Intimacy Enhancement, Living Healthy Together; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 15
States / cities: Anchorage, Alaska • Los Angeles, California • Orange, California + 11 more

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: photobiomodulation, Sham treatment, Physiotherapy; Device · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Surgery, Postoperative Blood Loss
Interventions: Tranexamic acid; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: End-stage Renal Disease
Interventions: tMBSR, Support group; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Colorectal Cancer, Neoplasms, Colorectal
Interventions: CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Beverly Hills, California • Fullerton, California • Washington D.C., District of Columbia + 3 more

Conditions: Caregiver Burden, Anxiety, Stress
Interventions: Heart Rate Variability Biofeedback, Music Listening Control; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination; Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Eating Disorders
Interventions: Dissonance Eating Disorder Prevention Program, Healthy Weight Intervention, Expressive Writing Control Condition; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 14 Years to 19 Years · Female only
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Interventions: inupadenant, Placebo, Carboplatin, Pemetrexed; Drug
Lead sponsor: iTeos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Tampa, Florida

Conditions: ST-elevation Myocardial Infarction (STEMI)
Interventions: zalunfiban, Placebo; Drug
Lead sponsor: CeleCor Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Anchorage, Alaska • Royal Oak, Michigan • St Louis, Missouri + 2 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Matching Placebo, Nintedanib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 11
States / cities: Danbury, Connecticut • Sarasota, Florida • Skokie, Illinois + 8 more

Search by objective public record fields.

Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy

Evaluating the Role of Pregabalin in Reducing Opioid Requirement in Spinal Fusion Surgeries of Two or More Vertebrae

Oxygenation Instability and Maturation of Control of Breathing in Premature Infants

Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)

Dose Response Study of Aerobic Exercise in Older Adults

WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits

Evaluating Feasibility and Acceptability of Pain Education

The HIIT Cognition Study

A Non-invasive Intervention (BreEStim) for Management of Phantom Limb Pain (PLP) After Limb Amputation (Experiment 2)

Family-based HIV Prevention for Adolescent Girls

Coping Together After Breast Cancer

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy

Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis

Journeys to Wellness: A Transplant Candidate Study

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

Caring Relationships Expression Study

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

Eating Disorder Prevention Programs

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)